Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial

Jesus Lovera, B. Bagert, K. Smoot, Cynthia Morris, R. Frank, K. Bogardus, Katherine Wild, Barry Oken, Ruth Whitham, Dennis Bourdette

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objectives: To determine if Ginkgo biloba (GB) improves the cognitive performance of subjects with multiple sclerosis (MS). Methods: Randomized, double-blind, placebo-controlled trial of GB, 120 mg twice a day or placebo for 12 weeks. The primary outcomes were: the long delay free recall from the California Verbal Learning Test-II; the Paced Auditory Serial Addition Test, the Controlled Oral Word Association Test; the Symbol Digit Modalities Test; Useful Field of View Test; and the color-word interference condition from the Stroop Color and Word Test. Results: On completion, the GB group (n = 20) was 4.5 seconds (95% confidence interval (Cl) (7.6, 0.9), P =0.015) faster than the placebo group (n = 18) on the color-word interference condition of the Stroop test. Subjects who were more impaired at baseline experienced more improvement with GB (treatment*baseline interaction, F=8.10, P=0.008). We found no differences on the other neuropsychological tests. Subjects on GB reported fewer cognitive difficulties in the Retrospective Memory Scale of the Perceived Deficits Questionnaire than subjects on placebo (1.5 points, 95% Cl (2.6, 0.3), P = 0.016). No serious drug related side-effects occurred and GB did not alter platelet function assays. Conclusion: Overall, GB did not show a statistically significant improvement in cognitive function. A treatment effect trend, limited to the Stroop test, suggests that GB may have an effect on cognitive domains assessed by this test, such as susceptibility to interference and mental flexibility.

Original languageEnglish (US)
Pages (from-to)376-385
Number of pages10
JournalMultiple Sclerosis
Volume13
Issue number3
DOIs
StatePublished - Apr 2007

Fingerprint

Ginkgo biloba
Multiple Sclerosis
Randomized Controlled Trials
Placebos
Stroop Test
Color
Word Association Tests
Verbal Learning
Neuropsychological Tests
Drug-Related Side Effects and Adverse Reactions
Double-Blind Method
Cognition
Blood Platelets
Confidence Intervals
Therapeutics

Keywords

  • Cognition
  • Double-blind method
  • Gibkgo biloba
  • Multiple sclerosis
  • Neuropsychological tests
  • Placebos
  • Quality of life
  • Randomized controlled trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis : A randomized, placebo-controlled trial. / Lovera, Jesus; Bagert, B.; Smoot, K.; Morris, Cynthia; Frank, R.; Bogardus, K.; Wild, Katherine; Oken, Barry; Whitham, Ruth; Bourdette, Dennis.

In: Multiple Sclerosis, Vol. 13, No. 3, 04.2007, p. 376-385.

Research output: Contribution to journalArticle

@article{71c6238e53534ad9a82b8571d77dc2f3,
title = "Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial",
abstract = "Objectives: To determine if Ginkgo biloba (GB) improves the cognitive performance of subjects with multiple sclerosis (MS). Methods: Randomized, double-blind, placebo-controlled trial of GB, 120 mg twice a day or placebo for 12 weeks. The primary outcomes were: the long delay free recall from the California Verbal Learning Test-II; the Paced Auditory Serial Addition Test, the Controlled Oral Word Association Test; the Symbol Digit Modalities Test; Useful Field of View Test; and the color-word interference condition from the Stroop Color and Word Test. Results: On completion, the GB group (n = 20) was 4.5 seconds (95{\%} confidence interval (Cl) (7.6, 0.9), P =0.015) faster than the placebo group (n = 18) on the color-word interference condition of the Stroop test. Subjects who were more impaired at baseline experienced more improvement with GB (treatment*baseline interaction, F=8.10, P=0.008). We found no differences on the other neuropsychological tests. Subjects on GB reported fewer cognitive difficulties in the Retrospective Memory Scale of the Perceived Deficits Questionnaire than subjects on placebo (1.5 points, 95{\%} Cl (2.6, 0.3), P = 0.016). No serious drug related side-effects occurred and GB did not alter platelet function assays. Conclusion: Overall, GB did not show a statistically significant improvement in cognitive function. A treatment effect trend, limited to the Stroop test, suggests that GB may have an effect on cognitive domains assessed by this test, such as susceptibility to interference and mental flexibility.",
keywords = "Cognition, Double-blind method, Gibkgo biloba, Multiple sclerosis, Neuropsychological tests, Placebos, Quality of life, Randomized controlled trials",
author = "Jesus Lovera and B. Bagert and K. Smoot and Cynthia Morris and R. Frank and K. Bogardus and Katherine Wild and Barry Oken and Ruth Whitham and Dennis Bourdette",
year = "2007",
month = "4",
doi = "10.1177/1352458506071213",
language = "English (US)",
volume = "13",
pages = "376--385",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis

T2 - A randomized, placebo-controlled trial

AU - Lovera, Jesus

AU - Bagert, B.

AU - Smoot, K.

AU - Morris, Cynthia

AU - Frank, R.

AU - Bogardus, K.

AU - Wild, Katherine

AU - Oken, Barry

AU - Whitham, Ruth

AU - Bourdette, Dennis

PY - 2007/4

Y1 - 2007/4

N2 - Objectives: To determine if Ginkgo biloba (GB) improves the cognitive performance of subjects with multiple sclerosis (MS). Methods: Randomized, double-blind, placebo-controlled trial of GB, 120 mg twice a day or placebo for 12 weeks. The primary outcomes were: the long delay free recall from the California Verbal Learning Test-II; the Paced Auditory Serial Addition Test, the Controlled Oral Word Association Test; the Symbol Digit Modalities Test; Useful Field of View Test; and the color-word interference condition from the Stroop Color and Word Test. Results: On completion, the GB group (n = 20) was 4.5 seconds (95% confidence interval (Cl) (7.6, 0.9), P =0.015) faster than the placebo group (n = 18) on the color-word interference condition of the Stroop test. Subjects who were more impaired at baseline experienced more improvement with GB (treatment*baseline interaction, F=8.10, P=0.008). We found no differences on the other neuropsychological tests. Subjects on GB reported fewer cognitive difficulties in the Retrospective Memory Scale of the Perceived Deficits Questionnaire than subjects on placebo (1.5 points, 95% Cl (2.6, 0.3), P = 0.016). No serious drug related side-effects occurred and GB did not alter platelet function assays. Conclusion: Overall, GB did not show a statistically significant improvement in cognitive function. A treatment effect trend, limited to the Stroop test, suggests that GB may have an effect on cognitive domains assessed by this test, such as susceptibility to interference and mental flexibility.

AB - Objectives: To determine if Ginkgo biloba (GB) improves the cognitive performance of subjects with multiple sclerosis (MS). Methods: Randomized, double-blind, placebo-controlled trial of GB, 120 mg twice a day or placebo for 12 weeks. The primary outcomes were: the long delay free recall from the California Verbal Learning Test-II; the Paced Auditory Serial Addition Test, the Controlled Oral Word Association Test; the Symbol Digit Modalities Test; Useful Field of View Test; and the color-word interference condition from the Stroop Color and Word Test. Results: On completion, the GB group (n = 20) was 4.5 seconds (95% confidence interval (Cl) (7.6, 0.9), P =0.015) faster than the placebo group (n = 18) on the color-word interference condition of the Stroop test. Subjects who were more impaired at baseline experienced more improvement with GB (treatment*baseline interaction, F=8.10, P=0.008). We found no differences on the other neuropsychological tests. Subjects on GB reported fewer cognitive difficulties in the Retrospective Memory Scale of the Perceived Deficits Questionnaire than subjects on placebo (1.5 points, 95% Cl (2.6, 0.3), P = 0.016). No serious drug related side-effects occurred and GB did not alter platelet function assays. Conclusion: Overall, GB did not show a statistically significant improvement in cognitive function. A treatment effect trend, limited to the Stroop test, suggests that GB may have an effect on cognitive domains assessed by this test, such as susceptibility to interference and mental flexibility.

KW - Cognition

KW - Double-blind method

KW - Gibkgo biloba

KW - Multiple sclerosis

KW - Neuropsychological tests

KW - Placebos

KW - Quality of life

KW - Randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=34248140642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248140642&partnerID=8YFLogxK

U2 - 10.1177/1352458506071213

DO - 10.1177/1352458506071213

M3 - Article

C2 - 17439907

AN - SCOPUS:34248140642

VL - 13

SP - 376

EP - 385

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 3

ER -